BioCentury
ARTICLE | Company News

Hemispherx, myTomorrows sales and marketing update

September 7, 2015 7:00 AM UTC

Hemispherx and myTomorrows launched Hemispherx’s Ampligen rintatolimod through an early access program in Europe and Turkey to treat chronic fatigue syndrome (CFS). The double-stranded RNA antiviral ...